In AJE: Missing data? Don't drop observations! A longitudinal study in Health and Retirement Study shows multiple imputation with predictive mean matching performs well, is easy to implement, and helps recover unbiased results doi.org/10.1093/aje/kw…

In this #OpenAccess TheJCPPadvances paper, Dr Yasmin Ahmadzadeh et al. explore longitudinal associations between mothers' emotional symptoms & child temperament traits & adjusted for genetic effects shared across generations. Read the full paper for more info. bit.ly/43IDwZ7

The 15th Annual Nordic PharmacoEpidemiological Network (NorPEN) Meeting will be in Oslo (22-24 Nov 2023): fhi.no/en/ab/conferen…. Deadline for abstract submission: 15 September 2023.

A bit of autumn in Northern Italy 🍁🍂

Aurora is really a thing in Norway 😅

We have exciting projects on drug repurposing in the era of large-scale observational and genetic data for MSCA postdoc candidates within the DS Train program at University of Oslo! Take a look lnkd.in/dRHKDX6H and apply here lnkd.in/d2CZDv4T

An unconventional way to celebrate Lunar New Year 🐲🐉

This replication cannot be done without the OMOP Common Data Model and the OHDSI federated analytic pipeline! Many thanks to all the colleagues that were involved! And yes, let's do this more @prieto_alhambra

Vaccination reduced the risk of #LongCovid by ~40% in the entire population (5.4 million) of Norway thelancet.com/journals/lanre… and reduced cardiovascular and thrombotic events Nhung Trinh The Lancet Respiratory Medicine

Do you plan on publishing a #disproportionality_analysis? Here the first #guidelines_for_reporting it: #READUS_PV! Now available on Drug Safety thanks to a massive collaboration between pharmacovigilance experts. doi.org/10.1007/s40264…

👉 Just published The READUS-PV guidelines on the Reporting of a Disproportionality Analysis for Drug Safety Signal Detection link.springer.com/article/10.100… link.springer.com/article/10.100… #OpenAcess #Pharmacovigilance

With Bessegen, my summer hiking season of 2024 comes to an end 🥳